Janus Henderson Group PLC
Market Movers (8-K)
NYSE
Janus Henderson Group plc has been acquired by Jupiter Company Limited in a take-private transaction valued at approximately $6.5 billion, with shares delisted from the NYSE.
Capital raise
NYSE
Janus Henderson Group plc announces receipt of regulatory and client approvals for its take-private transaction, with closing expected June 30, 2026.
Capital raise
NYSE
Janus Henderson Group plc's shareholders overwhelmingly approved director elections, executive compensation, and share repurchase authority at the 2026 Annual General Meeting.
NYSE
Janus Henderson Group plc reported Q1 2026 net inflows of US$2.9 billion and AUM of US$480 billion as it progresses toward a pending take-private acquisition.
NYSE
Janus Henderson Group plc shareholders have voted to approve the merger agreement with Jupiter Company Limited.
NYSE
Janus Henderson Group plc announced an amended all-cash merger agreement at $52 per share with Jupiter Company Limited, providing shareholders with compelling value and high certainty.
Better than expected
Quarterly Earnings (10-Q)
NYSE
Janus Henderson Group reports Q1 2026 results amid ongoing merger proceedings and strategic acquisition of Richard Bernstein Advisors.
Worse than expected
NYSE
Janus Henderson Group plc announced robust third-quarter 2025 results, driven by significant AUM growth and net inflows, alongside a non-binding acquisition proposal.
Better than expected
Capital raise
NYSE
Janus Henderson Group PLC announced a significant increase in Assets Under Management to $457.3 billion driven by strategic partnerships and market performance, alongside a new employment agreement for CEO Ali Dibadj and updates on ongoing legal proceedings.
NYSE
Janus Henderson Group's Q1 2025 results show an increase in AUM to $373.2 billion and diluted earnings per share of $0.77.
Worse than expected
NYSE
10-Q: Janus Henderson Group Reports Solid Q3 Performance Driven by Market Gains and Strategic Acquisitions
Janus Henderson Group saw a significant increase in assets under management and revenue in the third quarter of 2024, driven by positive market performance and strategic acquisitions.
Worse than expected
NYSE
Janus Henderson Group's Q2 2024 results show a significant increase in revenue and earnings per share, driven by strong investment performance and growth in assets under management.
Better than expected
Annual Reports (10-K)
NYSE
Janus Henderson Group plc announced a significant increase in net income and AUM for 2025, driven by strong performance fees and strategic partnerships, while also detailing its pending acquisition by Trian and General Catalyst.
Better than expected
Delay expected
Capital raise
NYSE
Janus Henderson Group's 2024 10-K filing reveals a 13% increase in AUM driven by positive market performance and solid long-term investment results.
NYSE
Janus Henderson Group grants a deferred incentive award in the form of performance-based share units to an employee, subject to specific terms and conditions.
Delay expected
Insider Trading (Form 4)
NYSE
Janus Henderson Group Ltd. announced the completion of its merger with Jupiter Company Limited, with shareholders receiving $52.00 per ordinary share in cash.
NYSE
Janus Henderson Group Ltd. has completed its merger with Jupiter Company Limited, with shareholders set to receive $52.00 per share in cash.
NYSE
Janus Henderson Group Ltd. announces the completion of its merger with Jupiter Company Limited, with Michelle Rosenberg reporting changes in beneficial ownership.
NYSE
Janus Henderson Group Ltd. announced the completion of its merger with Jupiter Company Limited, with director Leslie Seidman reporting changes in beneficial ownership.
NYSE
William B. Cassidy, Chief Technology Officer of Janus Henderson Group Ltd., reports changes in beneficial ownership following the company's merger completion and conversion of equity awards.
NYSE
Janus Henderson Group Ltd. announced the completion of its merger with Jupiter Company Limited, with shareholders receiving $52.00 per share in cash.
Proxy Statements (Def-14A)
NYSE
Janus Henderson Group plc filed its 2026 proxy statement detailing director elections, executive compensation, and a proposed merger with Trian and General Catalyst.
Better than expected
NYSE
Janus Henderson Group PLC's Special Committee has received an unsolicited, non-binding acquisition proposal while its take-private agreement with Trian and General Catalyst remains in effect.
NYSE
Janus Henderson Group plc confirmed receipt of an unsolicited non-binding proposal while its Board continues to recommend an existing $49.00 per share merger.
Delay expected
NYSE
Janus Henderson Group PLC announces a definitive agreement to be acquired by Trian and General Catalyst, transitioning to private ownership by mid-2026.
NYSE
Janus Henderson Group PLC announces upcoming proxy statement and shareholder vote regarding a significant proposed transaction.
Delay expected
NYSE
Janus Henderson Group PLC announces an agreement to go private in partnership with Trian and General Catalyst to accelerate future growth through strategic investments.
Capital raise
Institutional Holdings (13F)
NYSE
Janus Henderson Group PLC has filed an amendment to its Form 13F, reporting its institutional investment holdings as of March 31, 2026.
NYSE
Janus Henderson Group PLC has filed its quarterly Form 13F, reporting a total of 4,232 holdings with a total value of $201,677,061,421.
NYSE
Janus Henderson Group PLC has filed its Q4 2025 13F-HR report, revealing a substantial equity portfolio valued at over $223 billion across 4,350 positions.
NYSE
Janus Henderson Group PLC has filed its Form 13F-HR, revealing equity holdings valued at over $219 billion across 4,336 positions as of September 30, 2025.
NYSE
Janus Henderson Group PLC has filed its Q2 2025 13F-HR report, revealing over $204 billion in managed equity assets across 4,322 positions.
NYSE
Janus Henderson Group PLC's latest 13F filing reveals an extensive portfolio of 4,554 holdings valued at over $182 billion as of March 31, 2025.
Schedule 13D - Activist Investments
NYSE
Massachusetts Mutual Life Insurance Company reports no longer beneficially owning ordinary shares of Janus Henderson Group plc following the consummation of a merger agreement.
NYSE
Janus Henderson Group plc's merger with Parent and Merger Sub has been successfully consummated, with shareholders receiving $52.00 per share in cash.
NYSE
SCHEDULE: Janus Henderson Merger Closing Date Set
Janus Henderson Group PLC announces a revised closing date of June 30, 2026, for its merger with Jupiter Company Limited, subject to satisfaction of all conditions.
Delay expected
NYSE
Trian Fund Management has reduced its stake in Janus Henderson Group PLC by selling over 6.2 million shares at $51.60 per share.
NYSE
Trian-affiliated entities have amended the merger agreement for Janus Henderson Group PLC, increasing the cash consideration per share to $52 and adjusting termination fees.
Better than expected
Capital raise
NYSE
Massachusetts Mutual Life Insurance Company commits $1 billion in preferred equity to support the acquisition of Janus Henderson Group PLC by Jupiter Company Limited.
Capital raise
Schedule 13G - Passive Investments
NYSE
Janus Henderson Group Ltd. has reported beneficial ownership of 17.1% of Class I Shares in the Privacore VPC Asset Backed Credit Fund.
NYSE
Janus Henderson Group Ltd. has disclosed beneficial ownership of 2,800,000 Class I Shares, representing 46.8% of the outstanding shares, in the Privacore PCAAM Alternative Growth Fund.
NYSE
Janus Henderson Group Ltd. has reported beneficial ownership of 2,520,000 Class I Shares in Privacore PCAAM Alternative Income Fund, representing 67.4% of the class.
NYSE
SCHEDULE: Janus Henderson Discloses Biohaven Stake
Janus Henderson Group Ltd. has reported beneficial ownership of 5.7% of Biohaven Ltd. common shares as of June 30, 2026.
NYSE
Janus Henderson Group Ltd. has reported beneficial ownership of 10.6% of Jade Biosciences, Inc. common stock, totaling 6,273,262 shares, as of June 30, 2026.
NYSE
Janus Henderson Group plc has filed a Schedule 13G reporting beneficial ownership of 9.99% of Cellectar Biosciences, Inc. common stock.
Capital raise